Victor H Engelhard
Overview
Explore the profile of Victor H Engelhard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stasiak K, Stevens A, Bolte A, Curley C, Perusina Lanfranca M, Lindsay R, et al.
Cancer Immunol Immunother
. 2024 Nov;
74(1):10.
PMID: 39487854
Patients with metastatic brain melanomas (MBM) experience shorter-lasting survival than patients with extracranial metastases, and this is associated with a higher fraction of dysfunctional CD8 T cells. The goal of...
2.
Edmonds N, Gradecki S, Katyal P, Lynch K, Stowman A, Gru A, et al.
Oncoimmunology
. 2023 Jan;
12(1):2164476.
PMID: 36632563
Tertiary lymphoid structures (TLS) are ectopic lymphoid structures that can arise in human cancers and are associated with improved overall survival (OS) and response to immune checkpoint blockade (ICB) in...
3.
Lindsay R, Melssen M, Stasiak K, Annis J, Woods A, Rodriguez A, et al.
Front Oncol
. 2022 Dec;
12:1058894.
PMID: 36531040
Introduction: Studies of NK cells in tumors have primarily focused on their direct actions towards tumor cells. We evaluated the impact of NK cells on expression of homing receptor ligands...
4.
Rodriguez A, Parriott G, Engelhard V
Front Immunol
. 2022 Oct;
13:1009306.
PMID: 36189308
Tumor-associated tertiary lymphoid structures are ectopic lymphoid aggregates that have considerable morphological, cellular, and molecular similarity to secondary lymphoid organs, particularly lymph nodes. Tumor vessels expressing peripheral node addressin (PNAd)...
5.
Jaiswal A, Verma A, Dannenfelser R, Melssen M, Tirosh I, Izar B, et al.
Cancer Cell
. 2022 May;
40(5):524-544.e5.
PMID: 35537413
There is a need for better classification and understanding of tumor-infiltrating lymphocytes (TILs). Here, we applied advanced functional genomics to interrogate 9,000 human tumors and multiple single-cell sequencing sets using...
6.
Kwak M, Erdag G, Leick K, Bekiranov S, Engelhard V, Slingluff C
J Transl Med
. 2021 Aug;
19(1):371.
PMID: 34454518
Background: Immune cells in the tumor microenvironment have prognostic value. In preclinical models, recruitment and infiltration of these cells depends on immune cell homing (ICH) genes such as chemokines, cell...
7.
Lulu A, Cummings K, Jeffery E, Myers P, Underwood D, Lacy R, et al.
Cancer Immunol Res
. 2021 Aug;
9(11):1327-1341.
PMID: 34413086
Elevated immunity to cancer-expressed antigens can be detected in people with no history of cancer and may contribute to cancer prevention. We have previously reported that MHC-restricted phosphopeptides are cancer-expressed...
8.
Rodriguez A, Peske J, Woods A, Leick K, Mauldin I, Meneveau M, et al.
Cell Rep
. 2021 Jul;
36(3):109422.
PMID: 34289373
Tumor-associated tertiary lymphoid structures (TA-TLS) are associated with enhanced patient survival and responsiveness to cancer therapies, but the mechanisms underlying their development are unknown. We show here that TA-TLS development...
9.
Pinczewski J, Obeng R, Slingluff Jr C, Engelhard V
Pathol Res Pract
. 2021 Jun;
224:153527.
PMID: 34167064
β-catenin (βcat) is an important downstream effector in the Wnt signaling pathway and plays important roles in the development and progression of many cancers including melanoma. βcat expression is regulated...
10.
Lynch K, Young S, Meneveau M, Wages N, Engelhard V, Slingluff Jr C, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34103353
Background: Tertiary lymphoid structures (TLSs) are immune aggregates in peripheral tissues that may support adaptive immune responses. Their presence has been associated with clinical response to checkpoint blockade therapy (CBT),...